The LiBBY trial found that a research-only THC-plus-CBD oil reduced agitation scores in hospice-eligible dementia patients over 12 weeks. Adult children should avoid overreading the headline because the result applies only to that supervised formula, dose, and late-stage group. Agitation means restlessness, shouting, hitting, or resisting care. LiBBY was a 12-week, multicenter, randomized double-blind placebo-controlled Phase 2 study in 120 such patients, first reported at AAIC 2026 in London, according to the Alzheimer's Association Alzheimer's Association release.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What did LiBBY test?
- How large was the improvement?
- Who was in the study?
- What should adult children do next?
What did LiBBY test?
LiBBY tested a research-only oral oil taken twice daily. It contained 2 mg THC plus 100 mg CBD, called T2:C100.
That formula is not a dispensary or over-the-counter cannabis product, according to the Pennington Biomedical Research Center Pennington summary. Dose, purity, and supervision matter here. A store label with similar letters is not the same intervention.
How large was the improvement?
Treatment met its primary endpoint on the Cohen-Mansfield Agitation Inventory. Scores fell by 10.61 points versus 4.35 on placebo at week 2, a 6.27-point advantage sustained through week 12, according to NeurologyLive NeurologyLive report. Clinician ratings also favored treatment.
At week 12, 87.2% of THC/CBD patients had improved versus 23.6% on placebo, with most of the gap already present at week 2. The speed of separation matters for families. A two-week signal can look encouraging during exhausting days. It still reflects group averages, not a promise for any one parent.
Who was in the study?
Participants averaged 80 years old. They had advanced Alzheimer's or other dementia and hospice-level illness. Enrollment spanned 10 U.S.
sites with home-based visits. That design fits frail patients who cannot travel easily. These limits narrow the meaning. Results remain early topline conference findings from a small Phase 2 sample, so they do not establish an approved therapy or a general dementia treatment.
What should adult children do next?
Do not substitute store-bought CBD or THC. Benefit applies only to the supervised purified formulation and dose, with hospice-clinician guidance. Safety was mixed.
Overall adverse events were similar, but serious events were higher with THC/CBD, 23.3% versus 11.9%, including more serious infections and deaths, 13.1% versus 5.1%. Use the next hospice visit to ask focused questions: Bring a short log of when episodes happen, what helps, and current drugs and supplements. Ask the hospice clinician before adding or stopping any cannabis product.
- What is driving distress right now: pain, fear, noise, hunger, toileting, or medication effects?
- What non-drug steps can we try first for calming and sleep?
- Does this trial change anything in our current comfort-care plan?
- Who should we call if agitation suddenly worsens?
You Might Also Like
- LiBBY Trial Findings for Late-Stage Dementia Agitation in 2026: Questions Adult Children Can Ask About the Research
- p-tau217 Findings a Decade Before Alzheimer’s Symptoms in 2026: How Adult Children Can Avoid Overreading the Headline
- AAIC 2026 p-tau217 Alzheimer’s Risk Prediction Research: How Adult Children Can Avoid Overreading the Headline
